2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst G, Bedrosian I, Layman R, Carter J, Klein M, Venters S, Shad S, van der Noordaa M, Chien A, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu M, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Veer L, Valero V, Esserman L, Symmans W. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy. Annals Of Oncology 2021, 32: 642-651. PMID: 33617937, DOI: 10.1016/j.annonc.2021.02.011.Peer-Reviewed Original ResearchConceptsResidual cancer burdenI-SPY2 trialIndependent prognostic informationPrognostic informationBreast cancerPrognostic signaturePre-treatment tumor biopsiesHER2-negative breast cancerStage IIDistant relapse-free survivalMultivariate Cox regression modelHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Chemo-endocrine therapyEndocrine-based treatmentAdjuvant endocrine therapyGrowth factor receptor 2Primary outcome measureRelapse-free survivalSimilar prognostic informationCox regression modelMolecular prognostic signaturesNegative breast cancerFactor receptor 2MDACC cohort
2016
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
Jiang T, Shi W, Wali VB, Pongor L, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLOS Medicine 2016, 13: e1002193. PMID: 27959926, PMCID: PMC5154510, DOI: 10.1371/journal.pmed.1002193.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPathologic complete responseMD Anderson Cancer CenterNegative breast cancerBreast cancerMutation burdenExtensive residual diseaseBetter survival outcomesBRCA deficiencyImmune cell activityAnderson Cancer CenterPredictor of chemosensitivityHigh mutation burdenWhole-exome sequencingACT chemotherapyMDACC cohortTNBC cohortNeoadjuvant chemotherapyCare chemotherapyTaxane chemotherapyCancer Genome AtlasComplete responseSuch patientsImproved survivalAggressive disease